TREATING CANCERS WITH COMBINATIONS OF ANTI-CD20 ANTIBODY AND ACYLFULVENES
Application
US20260083691A1
Kind: A1
Mar 26, 2026
Assignee
Lantern Pharma Inc.
Inventors
Jianli Zhou, Kishor Bhatia
Abstract
A method of treating cancer includes administering a combination of active agents comprising a therapeutically effective amount of an acylfulvene, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an anti-CD20 antibody. The anti-CD20 antibody can be selected from rituximab, obinutuzumab, ofatumumab, and tositumomab. The cancer may be a B-cell cancer.
CPC Classifications
A61K 31/17
A61K 31/337
A61K 33/243
A61P 35/00
C07K 16/2887
A61K 2039/505
A61K 2039/545
Filing Date
2025-12-01
Application No.
19405201